These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 32392175)

  • 1. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin: First Global Approval.
    Kim ES
    Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
    Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
    Galinsky I; Coleman M; Fechter L
    Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
    DeAngelo DJ; George TI; Linder A; Langford C; Perkins C; Ma J; Westervelt P; Merker JD; Berube C; Coutre S; Liedtke M; Medeiros B; Sternberg D; Dutreix C; Ruffie PA; Corless C; Graubert TJ; Gotlib J
    Leukemia; 2018 Feb; 32(2):470-478. PubMed ID: 28744009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C-finding treated with midostaurin.
    Heiblig M; Gourguechon C; Guilpain P; Bulai-Livideanu C; Barete S; Chantran Y; Agopian J; Brenet F; Dubreuil P; Lespinasse J; Lemal R; Tournilhac O; Terriou L; Launay D; Bouillet L; Chatain C; Damaj G; Ballul T; Greco C; Polivka L; Frenzel L; Meni C; Bouktit H; Benabou D; Gaudy-Marqueste C; Gousseff M; Le Mouel E; Neel A; Ranta D; Jaussaud R; Molina TJ; Bruneau J; Villarese P; Lhermitte L; Maouche-Chrétien L; Temple M; Kosmider O; Javier RM; Pelletier F; Castelain F; Retornaz F; Cabrera Q; Zunic P; Gourin MP; Wierzbicka-Hainaut E; Viallard JF; Lavigne C; Hoarau C; Durieu I; Dimicoli-Salazar S; Torregrosa-Diaz JM; Wemeau M; Soria A; Arock M; Bodemer C; Lortholary O; Hermine O; Rossignol J
    Am J Hematol; 2024 Nov; 99(11):2127-2139. PubMed ID: 39287048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
    Singh A; Al-Kali A; Begna KH; Litzow MR; Larsen JT; Sher T; Abdelmagid MG; Farrukh F; Reichard KK; Gangat N; Pardanani A; Tefferi A
    Am J Hematol; 2022 May; 97(5):630-637. PubMed ID: 35156231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated safety of midostaurin plus chemotherapy in newly diagnosed
    Roboz GJ; Strickland SA; Litzow MR; Dalovisio A; Perl AE; Bonifacio G; Haines K; Barbera A; Purkayastha D; Sweet K
    Leuk Lymphoma; 2020 Dec; 61(13):3146-3153. PubMed ID: 32812818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
    Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
    Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
    Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
    Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
    Gotlib J; Kluin-Nelemans HC; George TI; Akin C; Sotlar K; Hermine O; Awan FT; Hexner E; Mauro MJ; Sternberg DW; Villeneuve M; Huntsman Labed A; Stanek EJ; Hartmann K; Horny HP; Valent P; Reiter A
    N Engl J Med; 2016 Jun; 374(26):2530-41. PubMed ID: 27355533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.